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Objectives: Multiple births are an important subgroup to consider in trials aimed at reducing 
preterm birth or its consequences. Including multiples results in a unique mixture of independent 
and clustered data, which has implications for the design, analysis and reporting of the trial. We 
aimed to determine how multiple births were taken into account in the design and analysis of 
recent trials involving preterm infants, and whether key information relevant to multiple births 
was reported. 
Design: We conducted a systematic review of multicentre randomised trials involving preterm 
infants published between 2008 and 2013. Information relevant to multiple births was extracted. 
Results: Of the 56 trials included in the review, 6 (11%) excluded multiples and 24 (43%) failed 
to indicate whether multiples were included. Among the 26 trials that reported multiples were 
included, only 1 (4%) accounted for clustering in the sample size calculations and 8 (31%) took 
the clustering into account in the analysis of the primary outcome. Of the 20 trials that 
randomised infants, 12 (60%) failed to report how infants from the same birth were randomised. 
Conclusions: Information on multiple births is often poorly reported in trials involving preterm 
infants, and clustering due to multiple births is rarely taken into account. Since ignoring 
clustering could result in inappropriate recommendations for clinical practice, clustering should 
be taken into account in the design and analysis of future neonatal and perinatal trials including 
infants from a multiple birth.  




Preterm birth is a leading cause of neonatal mortality and morbidity, and numerous 
randomised trials have assessed interventions aimed at reducing preterm birth or its negative 
health consequences. Multiple births are an important subgroup to consider in such trials, since 
multiples account for around a quarter of all preterm births and half of all twins are born 
preterm.[1] Including multiple births in a trial can be challenging due to the correlation between 
outcomes of infants from the same birth that results from shared environmental and genetic 
factors.[2 3] Correlated or clustered data are common in health research and methods for 
analysing this type of data are widely discussed.[4-8] Since trials involving preterm infants often 
include a mixture of singletons and multiples, or independent and clustered data, the implications 
of clustering in this unique setting require special attention. 
 
Analysis methods that either ignore or account for clustering due to multiple births have 
been examined over the last decade.[2 3 9-14] Failure to account for clustering in this setting can 
result in underestimated variances[9] and inflated type I error rates,[12] potentially leading to 
ineffective treatments being identified as effective. It is therefore recommended that clustering 
be taken into account in the analysis when infants from a multiple birth are included,[2 9 11-13] 
especially when the multiple birth rate is not low.[3 10]  Despite these recommendations, 
clustering is rarely taken into account in trials involving preterm infants. A systematic review of 
multicentre randomised trials involving preterm infants revealed that only 4 (21%) of the 19 
trials published between August 2003 and August 2008 that included multiples took the 
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clustering into account in the analysis.[11] It is unclear whether the practice of ignoring 
clustering in the analysis has continued in recent years.  
 
Clustering not only has implications for the analysis but also for the design and reporting 
of trials. Failure to account for clustering at the design stage could result in an underpowered 
trial that fails to identify a beneficial treatment, since clustering often reduces the effective 
sample size.[15] Whether clustering due to multiple births is taken into account in sample size 
calculations, and how this is achieved, remains to be investigated. At the reporting stage, details 
such as the prevalence of multiple births are important for assessing the appropriateness of the 
statistical methods and the generalisability of the trial findings. Inadequate reporting of neonatal 
and perinatal trials has previously been highlighted[11 16] but many aspects of reporting relevant 
to multiple births are yet to be considered. The aims of this systematic review are to determine 
how multiple births have been taken into account in the design and analysis of recently published 
multicentre randomised trials involving preterm infants, and whether key information relevant to 




This systematic review was conducted according to a pre-specified protocol. Consistent 
with the systematic review by Hibbs et al.,[11] the search focused on preterm infants, however 
defined in each individual trial, since multiple births are an important subgroup in this vulnerable 
population, and on multicentre randomised trials for feasibility. The search was conducted in 
PubMed on June 24, 2013 using the search terms “(preterm or premature) and (multicent* or 
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multi-cent*)” and the filters “Randomized Controlled Trial; published in the last 5 years; 
Humans; English; Newborn: birth-1 month”.  
 
Articles were eligible for inclusion if they reported the results of the primary outcome of 
a multicentre randomised trial, where the primary outcome was either measured on the infant or 
could be attributed to the infant. Where multiple articles reported on the primary outcome for the 
same trial, only the first published article was included to avoid duplication of information 
included in the review. The primary outcome was defined as the outcome identified by the 
authors as primary. If multiple primary outcomes were identified by the authors, it was defined 
as the outcome used to determine the sample size, provided only one outcome was used to 
determine the sample size, otherwise it was the first outcome identified by the authors as primary 
that met the eligibility criteria. If no primary outcome was identified by the authors, it was 
defined as the first outcome used to determine the sample size that met the eligibility criteria. 
Articles were excluded if none of the potential primary outcomes met the eligibility criteria, they 
described the methods of a trial only, or they reported the results of a pilot, phase I or phase II 
trial, a follow-up study of a trial, secondary outcomes or analyses of a trial, or multiple trials, 
including meta-analyses. However, articles primarily reporting the results of a single eligible trial 
and then adding these results to an existing meta-analysis were included.  
 
Titles and abstracts of all articles identified by the search were independently examined 
by two reviewers (including LNY) and classified as ineligible or eligible. The full text of all 
eligible titles and abstracts were then independently examined by two reviewers (LNY and TRS) 
to confirm eligibility and extract information using a purpose-specific data extraction form. 
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When assessing how multiple births were taken into account in the sample size and analysis, 





The search identified 164 articles, of which 56 (34.1%) met the inclusion criteria (Web 
Appendix) and were included in the review (Figure 1). For these 56 trials, the median 
(interquartile range (IQR)) sample size was 11 (4-22) centres and 214 (150-538) infants. There 
were 26 (46.4%) trials that indicated multiples were included and 24 (42.9%) trials where it was 
unclear whether multiples were included, either because the inclusion/exclusion criteria were not 
clearly stated (n=2 trials), or multiple births were eligible according to the inclusion/exclusion 
criteria but not otherwise mentioned (n=22 trials). Multiple births were excluded from the 
remaining 6 (10.7%) trials by either excluding women with a multiple pregnancy (n=5 trials) or 
excluding all infants from a multiple birth (n=1 trial). Only one trial justified the exclusion on the 
basis of the intervention previously being shown to be ineffective in women with multiple 
pregnancies. 
 
Characteristics of the 26 trials reporting that multiples were included are given in Table 1 
and their interventions and primary outcomes are provided in the Web Appendix. The median 
(IQR) percentage of infants from a multiple birth was 29.9% (23.9-33.3; n=24 trials where 
information clear). In 8 trials where infants were randomised and the method of randomising 
multiples was described, infants from the same birth were either randomised to the same 
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treatment group[17-22] or independently.[23 24] Two trials defined the primary outcome on the 
cluster level by assessing any occurrence of the outcome across infants from the same birth, 
while the primary outcome was defined on the infant level for the 24 remaining trials.  
 
Overall, 12 (46.2%) of the 26 trials including infants from a multiple birth took this into 
account in the design and/or analysis in some way (Table 2). Accounting for clustering was 
unnecessary for the two trials with a cluster level primary outcome. Clustering was otherwise 
neglected in the sample size calculations for all but one trial,[18] where the sample size was 
calculated assuming independence and then multiplied by a design effect of 1.12, with no 
justification provided for this choice of design effect. Clustering was addressed in the analysis of 
the primary outcome for 8 (30.8%) trials in either the primary analysis[18 21 25 26] or a 
sensitivity analysis.[19 20 22 23] In the latter case, treatment effects were clearly significant or 
non-significant and accounting for clustering did not alter the conclusions. The most common 
analysis approach used to account for clustering was generalised estimating equations.[18 19 21 
23 25] Other approaches included fitting a mixed effects model,[26] performing an adjusted chi-
square test[19] and analysing one infant per birth as a sensitivity analysis.[20 22] Where 
clustering was ignored in the sample size calculations or analysis, no justification was provided. 
Other approaches used to account for multiple births that do not address clustering included: 
stratifying on multiple birth in the randomisation;[19 27] adjusting for multiple birth in the 
analysis as a fixed effect in a sensitivity analysis;[24 28] testing for a treatment by multiple birth 
interaction;[26 27] and performing subgroup analyses for singletons to assess the influence of 
including twins,[20] or both singletons and multiples to assess consistency of treatment 
effects.[27 29] 
Page 8 of 21 
 
 
For the 26 trials including infants from a multiple birth, the percentage of missing data 
for the primary outcome ranged from 0% to 7.2% and was unclear in 6 (23.1%) trials. Only one 
trial performed multiple imputation to account for missing data and no information was provided 
on how multiple births were taken into account in the imputation process.[21] 
 
Key details relevant to multiple births were not reported in some trial publications (Table 
1). The percentage of infants from a multiple birth could be determined in all but 2 (7.7%) trials, 
while the percentage of women with a multiple pregnancy could only be determined in 7 (26.9%) 
trials. Among the 20 trials including multiples and randomising infants, 12 (60.0%) did not 
specify how infants from the same birth were randomised. No trial reported the intracluster 





Our systematic review demonstrates that clustering due to multiple births is rarely 
considered in the design and remains ignored in the analysis of many multicentre randomised 
trials involving preterm infants. It also highlights that information relevant to multiple births is 
poorly reported. It was unclear whether infants from a multiple birth were even included in 
almost half of the trials in our review, making it impossible to assess whether appropriate 
methods were used to calculate the sample size and analyse the data. When infants from a 
multiple birth were included, details such as how infants from the same birth were randomised 
were often not provided. This information is important, since the impact of clustering on the 
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power of the trial depends on the method used to randomise multiples.[30] Overall, our review 
indicates that the problems identified in the previous systematic review[11] are yet to be 
resolved, and identifies new areas where multiple births are inadequately handled. Clearly, 
substantial room for improvement remains in the way multiple births are dealt with in trials 
involving preterm infants. 
 
To avoid conducting an underpowered trial, it is important to account for clustering due 
to multiple births in the sample size calculations, which typically requires an estimate of the 
ICC.[5 15]  Unfortunately, ICCs relevant to multiple births are lacking in the literature and none 
of the trials in our review reported ICCs. This may help to explain why clustering was only 
addressed in the sample size calculations for one trial in our review. ICCs should be reported to 
comply with reporting guidelines[31] and assist with sample size planning for future trials.[15 
32]  
 
Ignoring clustering in the analysis can lead to substantially biased standard errors and 
potentially result in false conclusions being drawn from the data.[33] In practice, this could mean 
an effective intervention is missed or an ineffective intervention is recommended. While 
conclusions about the effectiveness of treatment were unaltered in the few trials in our review 
that reported analysing the data both with and without adjustment for clustering, we have 
previously demonstrated that adjustment for clustering due to multiple births can change 
conclusions.[12] The most popular analysis method used to account for clustering in our review 
was generalised estimating equations. This method is relatively simple to implement, is available 
in many statistical software packages, and has been shown to perform well for analysing trials 
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including both singletons and multiples,[12] making it a good choice in practice. Another 
popular analysis approach identified in our review was removing the clustering and analysing 
only one infant per mother. This method is not recommended, since it reduces the sample size 
and hence the power of the trial, and has the potential to produce different results depending on 
the infants selected.[2]. For a more detailed discussion of methods for analysing trials including 
infants from a multiple birth, see [2 3 9-14]. 
 
While use of methods that account for clustering was limited among the trials in our 
review, multiple births were sometimes considered in the design and analysis in other ways, 
which suggests an awareness of the potential for multiples to have an impact on the trial results. 
At the design stage, some trials used multiple birth as a stratification variable in the 
randomisation, which ensures approximate balance between treatment groups in the multiple 
birth rate, independent of how infants from the same birth are randomised. This approach may be 
useful in trials where multiple birth status is strongly related to the outcome, since a chance 
imbalance could influence the estimated treatment effect and reduce trial credibility. 
Stratification can also reduce type I error rates and increase power.[34] At the analysis stage, 
some trials adjusted for multiple birth, tested for a treatment by multiple birth interaction, or 
performed subgroup analyses based on multiple birth status. Adjustment controls for chance 
imbalance in the multiple birth rate between treatment groups and can increase power.[35] 
Interaction tests and subgroup analyses assess whether the magnitude of the treatment effect 
differs between singletons and multiples, and may help to determine which infants benefit from 
treatment, but should be interpreted with caution as they are likely to be underpowered.[36] 
While these approaches may provide useful information about imbalance and effect 
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modification, they do not overcome the problems associated with ignoring clustering in the 
analysis and should not be considered essential.  
 
Imputation is a useful method for dealing with missing data in randomised trials, 
although only one trial included in our review applied this method. When clustering is present in 
the data, this should be taken into account in the imputation model but current strategies are 
infeasible in neonatal and perinatal trials due to the small cluster sizes.[37 38] Developing 
imputation methods suitable for handling clustering due to multiple births is an important area 
for future research.  
 
A limitation of this systematic review is that information was extracted from the 
published articles only. Some details that were missing or unclear may have been obtainable 
from published trial protocols or by contacting the authors. As a result, we may have over or 
underestimated the prevalence of published trials that ignored clustering due to multiple births. 
Improved reporting around multiple births is important for future trials so that the 
appropriateness of the chosen statistical methods can adequately be assessed. This can be 
achieved through publication of additional information in supplementary materials online, 
stricter adherence to general reporting guidelines,[31 39] and the development of reporting 
guidelines specifically for trials including infants from multiple births. 
 
In conclusion, clustering due to multiple births continues to be ignored in the design, 
analysis and reporting of many trials involving preterm infants. Given the potential impact of 
ignoring clustering, including underpowered trials and incorrect conclusions that could lead to 
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inappropriate recommendations for clinical practice, clustering should be taken into account in 
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What is already known on this topic 
• Including multiple births in randomised trials results in clustering in the data. 
• Clustering has implications for the design, analysis and reporting of trials. 
What this study adds 
• Clustering due to multiple births is often ignored in the trial design and analysis but 
should be taken into account. 
• Information relevant to multiple births is poorly described and reporting guidelines 
 are needed. 
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Table 1: Characteristics of trials including infants from multiple births 
Characteristic Trials (N=26) 
Percentage of women with a multiple pregnancy   
- median (IQR)* 20.0 (1.5-22.2) 
- unclear: n (%) 19 (73.1) 
Percentage of infants from a multiple birth  
- median (IQR)* 29.9 (23.9-33.3) 
- unclear: n (%) 2 (7.7) 
Highest order multiples included in the trial: n (%)  
- twins 7 (26.9) 
- higher order multiples 9 (34.6) 
- unclear 10 (38.5) 
Who was randomised: n (%)  
- mother 6 (23.1) 
- infant 20 (76.9) 
Timing of the intervention: n (%)  
- prenatal 6 (23.1) 
- postnatal 20 (76.9) 
Who received the intervention: n (%)  
- mother  6 (23.1) 
- infant 18 (69.2) 
- mother/parents and infant 2 (7.7) 
Level of the primary outcome: n (%)  
- cluster level 2 (7.7) 
- infant level 24 (92.3) 
 
* Based on the trials where the percentage was not unclear 
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Table 2: Approaches used to account for multiple births in the design and analysis of trials 
including infants from multiple births 
Approach n (%) Trials 
(N=26) 
References 
Accounted for clustering in the sample size 
calculation for the primary outcome 
1 (3.9) [18] 
Accounted for clustering in the analysis of the 
primary outcome 
8 (30.8) [18-23 25 26] 
Stratified by multiple birth in the randomisation 2 (7.7) [19 27] 
Adjusted for multiple birth as a fixed effect for the 
primary outcome 
2 (7.7) [24 28] 
Tested for treatment x multiple birth interaction for 
the primary outcome 
2 (7.7) [26 27] 
Performed analysis in subgroup(s) based on multiple 
birth for the primary outcome 
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2. Interventions and Primary Outcomes for the 26 Trials Including Multiple Births 
Trial Interventions Primary Outcome* 
Blanken et al.[1] Monthly palivizumab 
injections vs placebo 
Total number of parent reported 
wheezing days in the first year of 
life 
Schmidt et al.[2] Pulse oximiters displaying 
oxygen saturations 3% 
higher vs lower than the true 
value 
Composite of death, gross motor 
disability, cognitive or language 
delay, severe hearing loss or 
bilateral blindness at 18 months 
corrected age 
Roos et al.[3] Maintenance tocolysis with 
nifedipine orally vs placebo 
Composite of perinatal death, 
chronic lung disease, neonatal 
sepsis, intraventricular 
haemorrhage >grade 2, 
periventricular leukomalacia 
>grade 1 or necrotizing 
enterocolitis up to 6 months of age 
Fergusson et al.[4] Transfusion of red blood 
cells stored 7 days or less vs 
standard issue red blood 
cells 
Composite of necrotizing 
enterocolitis, retinopathy of 
prematurity, bronchopulmonary 
dysplasia, intraventricular 
haemorrhage or death while in the 
neonatal intensive care unit up to 
90 days 
van der Ham et al.[5] Expectant management vs 
induction of labour 
Neonatal sepsis  
van der Ham et al.[6] Expectant management vs 
induction of labour 
Neonatal sepsis 
Leaf et al.[7] Early vs late commencement 
of enteral feeds 
Time to achieve full enteral 
feeding sustained for 72 hours 
Ramanathan et al.[8] Nasal intermittent positive 
pressure ventilation vs nasal 
continuous positive airway 
pressure 
Need for mechanical ventilation 
via endotracheal tube at 7 days of 
age 
Cignacco et al.[9] Oral sucrose vs facilitated 
tucking vs combined oral 
sucrose and facilitated 
tucking 
Pain response measured on the 
Bernese Pain Scale for Neonates 
Dunn et al.[10] Prophylactic surfactant vs 
intubate-surfactant-extubate 
vs nasal continuous positive 
airway pressure 
Death or bronchopulmonary 
dysplasia at 36 weeks 
postmenstrual age 
Gopel et al.[11] Surfactant without 
ventilation vs standard care 
Need for mechanical ventilation or 
not being ventilated but having 
pCO2>65mmHg or FiO22>0.60 or 
both for more than 2 hours 
between 25 and 72 hours of age 
New et al.[12] Transfer to an open cot at 
1600 vs 1800g 
Average daily weight gain over the 
first 14 days following transfer to 
an open cot 
Rubin et al.[13] Carotenoid supplemented 
formula vs control formula 
Plasma lutein concentration 
Zachariassen et al.[14] Unfortified vs fortified 
mother's milk 
Weight 
Mintz-Hittner et al.[15] Conventional laser therapy 
vs intravitreal bevacizumab 
monotherapy 
Recurrence of neovascularization 
in one or both eyes arising from 
the retinal vessels and requiring 
retreatment by 54 weeks 
postmenstrual age 
Mercier et al.[16] Inhaled nitric oxide vs 
placebo gas 
Survival without development of 
bronchopulmonary dysplasia at 36 
weeks postmenstrual age 
Carlo et al.[17] Target range of oxygen 
saturation of 85-89% vs 81-
95% 
Composite of severe retinopathy 
of prematurity or death before 
hospital discharge 
Sandri et al.[18] Prophylactic surfactant 
followed by nasal 
continuous positive airway 
pressure vs early nasal 
Need for mechanical ventilation in 
the first 5 days of life 
continuous positive airway 
pressure followed by early 
selective surfactant 
Ortenstrand et al.[19] Family care ward vs 
standard care ward 
Total length of hospital stay 
Carbonell-Estrany et al.[20] Monthly motavizumab vs 
palivizumab injections 
Positive respiratory syncytial virus 
(RSV) test and hospitalised for 
respiratory symptoms or new onset 
of RSV-positive lower respiratory 
illness with worsening respiratory 
status while already in hospital or 
death caused by RSV 
Garite et al.[21] Single rescue course of 
betamethasone vs placebo 
Composite of respiratory distress 
syndrome, bronchopulmonary 
dysplasia, severe intraventricular 
haemorrhage, periventricular 
leukomalacia, blood culture 
proven sepsis, necrotizing 
enterocolitis or perinatal death 
Carr et al.[22] Granulocyte-macrophage 
colony stimulating factor vs 
standard management 
Survival without an episode of 
culture positive systemic sepsis to 
14 days from trial entry 
Makrides et al.[23] High vs standard 
docosahexaenoic acid enteral 
feeds 
Bayley Mental Development Index 
at 18 months corrected age 
Murphy et al.[24] Multiple courses of antenatal 
corticosteroids vs placebo 
Composite of perinatal or neonatal 
mortality, severe respiratory 
distress syndrome, intraventricular 
haemorrhage >grade 2, 
periventricular leukomalacia, 
bronchopulmonary dysplasia or 
necrotizing enterocolitis 
Koldewijn et al.[25] Infant Behavioural 
Assessment and Intervention 
Program vs standard care 
Bayley Mental Development Index 
at 6 months corrected age 
Rouse et al.[26] Magnesium sulfate vs 
placebo 
Composite of stillbirth or infant 
death by 1 year corrected age or 
moderate or severe cerebral palsy 
at or beyond 2 years corrected age 
 
* According to the definition described in the Methods. All outcomes relate to the infant. 
 

